secwatch.observer — SEC 8-K summary
======================================

Issuer:     Opus Genetics, Inc. (IRD)
CIK:        0001228627
Form:       8-K
Filed at:   2025-06-20T23:59:59+00:00
Accession:  0001140361-25-023172
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 1.01
LLM model:  deepseek-v4-flash:cloud@v2

Opus Genetics secures up to $2M nondilutive funding from Foundation Fighting Blindness for MERTK gene therapy
--------------------------------------------------------------------------------

- Up to $2,000,000 nondilutive funding from Foundation Fighting Blindness Retinal Degeneration Fund for MERTK gene therapy program.
- $1,000,000 disbursed upfront; up to $1,000,000 additional upon milestone achievement.
- Company must meet development milestones; failure triggers obligation to out-license program.
- Regulatory milestone triggers payment equal to total funded amount; tiered royalties until 300% repayment.
- On change of control, RDF may require buy-out at 100% of funded amounts.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1228627/000114036125023172/0001140361-25-023172-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1228627/000114036125023172/ef20050845_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-25-023172

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer